Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage biopharmaceutical company developing oncology therapies that exploit specific vulnerabilities in cancer cell mutations while aiming to spare healthy tissue. News about Aprea focuses on the progress of its precision oncology pipeline, centered on DNA damage response–related targets.
The company’s updates frequently cover clinical data from its lead programs. APR-1051, an oral WEE1 kinase inhibitor, is being studied in the biomarker-focused Phase 1 ACESOT-1051 trial in advanced solid tumors. Press releases describe early signals of anti-tumor activity and disease stabilization in heavily pretreated gastrointestinal, gynecologic, and HPV-positive head and neck cancers, as well as details on dose escalation, safety, and biomarker-defined patient cohorts.
News flow also highlights ATRN-119, Aprea’s macrocyclic ATR inhibitor in the Phase 1/2a ABOYA-119 trial. The company reports identification of a recommended Phase 2 dose for once-daily dosing, early evidence of disease stabilization, and examples of tumor shrinkage in patients with DDR-related gene mutations. Recent announcements describe a strategic shift toward evaluating ATRN-119 in combination with radiation, immune checkpoint inhibitors, and antibody-drug conjugates, and the pausing of further monotherapy enrollment.
Investors following APRE news will also see regular financial results releases, updates on cash runway, private placement financings, and participation in scientific and investor conferences such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the H.C. Wainwright Global Investment Conference. Together, these items provide an ongoing view of Aprea’s clinical development milestones, research collaborations, and corporate activities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aprea Therapeutics (Nasdaq: APRE) reported financial results for 2022, highlighting its focus on developing cancer therapeutics targeting DNA damage response pathways. The company initiated its Phase 1/2a clinical trial for ATR inhibitor ATRN-119 and secured approximately $5.5 million from a public offering to extend its cash runway to Q3 2024. Cash and equivalents stood at $28.8 million as of December 31, 2022. Aprea experienced a reduced operating loss of $2.7 million in Q4 2022, down from $7.8 million in Q4 2021. The year-end net loss was $112.7 million, a significant increase from $37.1 million in 2021, primarily due to acquired in-process research and development costs.